Literature DB >> 3539321

Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).

B A Teicher, S A Holden, M J Kelley, T C Shea, C A Cucchi, A Rosowsky, W D Henner, E Frei.   

Abstract

We have developed a human head and neck squamous cell carcinoma cell line (SCC-25/CP) which is relatively stably resistant to cis-diamminedichloroplatinum(II) (CDDP) after repeated exposure to escalating doses of the drug. The studies reported elucidate the mechanism(s) by which the SCC-25/CP cell line is resistant to CDDP. The SCC-25/CP cell line is approximately 30-fold resistant to CDDP, approximately 10-fold resistant to carboplatin, and about 9-fold resistant to iproplatin. Using [195mPt]CDDP, we examined the levels of platinum in whole cells and cellular fractions of both the SCC-25 and SCC-25/CP cells after 1 h exposure to 100 microM drug. The SCC-25 cells took up 30 pmol of platinum/10(6) cells in 1 h; 64% of the drug was in the nucleus and 21% in the cytosol. The SCC-25/CP cells took up 7 pmol of platinum/10(6) cells; of this, 41% was in the nucleus and 33% in the cytosol. The SCC-25 cell nuclei contained 331 pmol of platinum/mg protein and the cytosol 21 pmol of platinum/mg protein, whereas the SCC-25/CP cell nuclei contained 47 pmol of platinum/mg protein and the cytosol 8.1 pmol/mg protein. The release of drug from both cell lines followed a very similar course and was most rapid over the first 6 h. There was no difference in the non-protein sulfhydryl content of the cell lines. The protein sulfhydryl content, as measured by Ellman's procedure, indicated that the SCC-25/CP cell line has approximately a 2-fold increase in protein sulfhydryl content compared to the SCC-25 cell line. The SCC-25/CP cell line is about 2-fold resistant to cadmium chloride at 50% cell kill and about 2.5-fold resistant at 1 log kill compared to the SCC-25 cell line. Glutathione transferase activity in crude cytoplasmic extracts was measured and found to be approximately 2- to 3-fold higher in the CDDP resistant cells. The isoelectric point of the glutathione transferase isozyme was 4.8 in both the sensitive and resistant cell lines, suggesting induction of the predominant isozyme present in the parent cell line. By alkaline elution there was greater cross-link formation by CDDP in the SCC-25 cell line than in the SCC-25/CP cell line at the same drug concentrations. In conclusion, the mechanism of resistance of the SCC-25/CP cell line to CDDP is multifactorial, involving plasma membrane changes, increased cytosolic binding, and decreased DNA cross-linking.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3539321

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.

Authors:  K Ikeda; K Miura; S Himeno; N Imura; A Naganuma
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

3.  In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.

Authors:  G Chen; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 4.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis.

Authors:  Noriyoshi Miura; Nobuaki Takemori; Tadahiko Kikugawa; Nozomu Tanji; Shigeki Higashiyama; Masayoshi Yokoyama
Journal:  Mol Oncol       Date:  2012-01-04       Impact factor: 6.603

6.  ATP11B mediates platinum resistance in ovarian cancer.

Authors:  Myrthala Moreno-Smith; J B Halder; Paul S Meltzer; Tamas A Gonda; Lingegowda S Mangala; Rajesha Rupaimoole; Chunhua Lu; Archana S Nagaraja; Kshipra M Gharpure; Yu Kang; Cristian Rodriguez-Aguayo; Pablo E Vivas-Mejia; Behrouz Zand; Rosemarie Schmandt; Hua Wang; Robert R Langley; Nicholas B Jennings; Cristina Ivan; Jeremy E Coffin; Guillermo N Armaiz; Justin Bottsford-Miller; Sang Bae Kim; Margaret S Halleck; Mary J C Hendrix; William Bornman; Menashe Bar-Eli; Ju-Seog Lee; Zahid H Siddik; Gabriel Lopez-Berestein; Anil K Sood
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

7.  Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.

Authors:  B A Teicher; D Chatterjee; J T Liu; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.

Authors:  W Zhen; C J Link; P M O'Connor; E Reed; R Parker; S B Howell; V A Bohr
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

Review 10.  Chemotherapeutic drug resistance in the management of head and neck cancer.

Authors:  H Bier
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.